Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

被引：151

作者：

Ito-Horiyama, Tsukasa ^{[1
]}

Ishii, Yoshikazu ^{[2
]}

Ito, Akinobu ^{[1
]}

Sato, Takafumi ^{[1
]}

Nakamura, Rio ^{[1
]}

Fukuhara, Norio ^{[3
]}

Tsuji, Masakatsu ^{[1
]}

Yamano, Yoshinori ^{[1
]}

Yamaguchi, Keizo ^{[2
]}

Tateda, Kazuhiro ^{[2
]}

机构：

[1] Shionogi & Co Ltd, Discovery Res Lab Core Therapeut Areas, Osaka, Japan

[2] Toho Univ, Sch Med, Tokyo, Japan

[3] Shionogi & Co Ltd, Global Innovat Off, Osaka, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2016年 / 60卷 / 07期

关键词：

D O I：

10.1128/AAC.03098-15

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

To better understand the antibacterial activity of S-649266 against carbapenemase producers, its stability against clinically relevant carbapenemases was investigated. The catalytic efficiencies (k(cat)/K-m) of IMP-1, VIM-2, and L1 for S-649266 were 0.0048, 0.0050, and 0.024 mu M-1 s(-1), respectively, which were more than 260-fold lower than that for meropenem. Only slight hydrolysis of S-649266 against KPC-3 was observed. NDM-1 hydrolyzed meropenem 3-fold faster than S-649266 at 200 mu M.

引用

页码：4384 / 4386

页数：3

共 50 条

[21] Enhancement in dentin collagen's biological stability after proanthocyanidins treatment in clinically relevant time periods
Liu, Yi
Chen, Mingsheng
Yao, Xiaomei
Xu, Changqi
Zhang, Ying
Wang, Yong
DENTAL MATERIALS, 2013, 29 (04) : 485 - 492
[22] Pseudocin 196, a novel lantibiotic produced by Bifidobacterium pseudocatenulatum elicits antimicrobial activity against clinically relevant pathogens
Sanchez-Gallardo, Rocio
O'Connor, Paula M.
O'Neill, Ian J.
McDonnell, Brian
Lee, Ciaran
Moore, Rebecca L.
McAuliffe, Fionnuala M.
Cotter, Paul D.
van Sinderen, Douwe
GUT MICROBES, 2024, 16 (01)
[23] Novel double and triple antibiotic combinations at clinically relevant concentrations against polymyxin B resistant Pseudomonas aeruginosa
Bear, Michael D.
Suen, Amy
Lenhard, Justin
Bulman, Zackery
Ly, Neang S.
Rao, Gauri
Holden, Patricia N.
Tsuji, Brian T.
PHARMACOTHERAPY, 2013, 33 (10): : E278 - E278
[24] In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
Kazmierczak, Krystyna M.
Tsuji, Masakatsu
Wise, Mark G.
Hackel, Meredith
Yamano, Yoshinori
Echols, Roger
Sahm, Daniel F.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 53 (02) : 177 - 184
[25] In vitro and in vivo activity of GT-1, a novel siderophore cephalosporin, and GT-055, a broad-spectrum β-lactamase inhibitor, against biothreat and ESKAPE pathogens
Halasohoris, Stephanie A.
Scarff, Jennifer M.
Pysz, Lisa M.
Lembirik, Sanae
Lemmon, Margaret M.
Biek, Donald
Hannah, Brendan
Zumbrun, Steven D.
Panchal, Rekha G.
JOURNAL OF ANTIBIOTICS, 2021, 74 (12): : 884 - 892
[26] In vitro and in vivo activity of GT-1, a novel siderophore cephalosporin, and GT-055, a broad-spectrum β-lactamase inhibitor, against biothreat and ESKAPE pathogens
Stephanie A. Halasohoris
Jennifer M. Scarff
Lisa M. Pysz
Sanae Lembirik
Margaret M. Lemmon
Donald Biek
Brendan Hannah
Steven D. Zumbrun
Rekha G. Panchal
The Journal of Antibiotics, 2021, 74 : 884 - 892
[27] In Silico Design, Synthesis, and In Vitro Evaluation of Novel Amphipathic Short Linear Peptides Against Clinically Relevant Bacterial Biofilms
Darwish, Shaban
Noreddin, Ahmed
Tiwari, Rakesh
Elkhatib, Walid F.
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2019, 25 (03) : 1075 - 1085
[28] Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjogren's syndrome: A critical review
Vilchez-Oya, Francisco
Martin, Hector Balastegui
Garcia-Martinez, E.
Corominas, Hector
FRONTIERS IN IMMUNOLOGY, 2022, 13 : 1003054
[29] In Silico Design, Synthesis, and In Vitro Evaluation of Novel Amphipathic Short Linear Peptides Against Clinically Relevant Bacterial Biofilms
Shaban Darwish
Ahmed Noreddin
Rakesh Tiwari
Walid F. Elkhatib
International Journal of Peptide Research and Therapeutics, 2019, 25 : 1075 - 1085
[30] Pre-clinical characterization of a novel series of FGFR2 selective inhibitors with potency against clinically relevant mutations
Fischer, John
Bouhana, Karyn
Chicarelli, Mark J.
Dahlke, Josh
Fell, Brad
Fulton, Jennifer
Guarnieri, Anna
Jalluri, Ravi
Johnson, Amber
Mclean, Brent
Mejia, Max
Rieger, Rob
Robinson, John
Rodriguez, Mareli
Sullivan, Francis
Wang, Yang
Winski, Shannon
Zhou, Yeyun
CANCER RESEARCH, 2022, 82 (12)

← 1 2 3 4 5 →